Marco Ruella
Hematology
3400 Civic Center Boulevard
West Pavilion, 4th Floor
Philadelphia, PA 19104
West Pavilion, 4th Floor
Philadelphia, PA 19104
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 144 publications
Publisher Correction: Decade-long persistence of CD19 CAR T cells in B cell lymphomas.
Journal: Nature medicine
Published: August 26, 2026
CAR T cells against the B cell receptor to precisely eliminate pathogenic B cells.
Journal: Molecular therapy. Oncology
Published: August 14, 2026
CART-immune-related adverse events after BCMA CAR-T therapy.
Journal: Molecular therapy. Oncology
Published: July 11, 2026
Ten-Year Outcomes after CAR T-Cell Therapy for B-Cell Lymphomas.
Journal: The New England journal of medicine
Published: June 24, 2026
Cis-targeted IL-2 mutein to augment the anti-tumor activity of engineered T cells.
Journal: Transplantation and cellular therapy
Published: May 23, 2026
Differential cytokine architecture in patients treated with CART19 versus CART22.
Journal: Journal for immunotherapy of cancer
Published: May 21, 2026
SPTBN2 promotes an immunosuppressive tumor microenvironment and cross-resistance to anti-cancer therapies.
Journal: bioRxiv : the preprint server for biology
Published: April 10, 2026
The ancestral haplotype of P2RX5 yields a B-cell surface marker and a multi-lineage immunotherapy target.
Journal: bioRxiv : the preprint server for biology
Published: February 06, 2026
Chimeric antigen receptor T cells against the IGHV4-34 B cell receptor specifically eliminate neoplastic and autoimmune B cells.
Journal: Science translational medicine
Published: February 04, 2026
Decade-long persistence of CD19 CAR T cells in B cell lymphomas.
Journal: Nature medicine
Published: December 18, 2025
Last Updated: 09/26/2026